|Articles|August 4, 2016
New CEO for Inspyr Therapeutics
August 04, 2016
Advertisement
Inspyr Therapeutics, Inc. (San Antonio, TX) has appointed Christopher Lowe as President and Chief Executive Officer, and as a member of the Company’s Board of Directors. Mr. Lowe brings more than 15 years of executive management experience in life sciences as CEO, Chief Financial Officer and Chief Business Officer, and has been an advisor to the Inspyr’s Board of Directors since March 2016.
Newsletter
Lead with insight with the Pharmaceutical Executive newsletter, featuring strategic analysis, leadership trends, and market intelligence for biopharma decision-makers.
Advertisement
Related Content
Advertisement
Advertisement
Advertisement
Trending on PharmExec
1
Brent Saunders: Eyeing New Horizons
2
FDA Approves Enhertu Plus Perjeta as First-Line Therapy for HER2-Positive Metastatic Breast Cancer
3
FDA Grants National Priority Voucher to Tecvayli Combination in Relapsed or Refractory Multiple Myeloma
4
Sobi Reaches $1.5 Billion Definitive Agreement with Arthrosi Therapeutics to Acquire Gout Treatment
5
